ArQule
Home
Contact
Careers
About
About ArQule
Management
Board of Directors
Business Development
Scientific Partners
Commercial Partners
Careers
News & Events
Science
Overview
Targeted Approach
BTK Inhibitor (ARQ 531)
Early Stage Programs
Pipeline
Overview
Tivantinib (ARQ 197)
ARQ 087
ARQ 092
ARQ 761
ARQ 751
Oncology Clinical Trials
Rare Diseases Clinical Trials
Publications & Presentations
Investors & Media
Investor Overview
Press Releases
Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor & Media FAQs
Investor & Media Contact
Twitter
LinkedIn
Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma
Tuesday, September 1, 2015
Posters and Presentations
News & Events
Posters and Presentations
Press Releases
Publications
Questions or Concerns?
Please feel free to contact by one of the methods below
Online Form
Call (781) 994-0300
About
Management
Board of Directors
Business Development
Scientific Partners
Commercial Partners
Careers
News & Events
Contact
Pipeline
Tivantinib (ARQ 197)
ARQ 087
ARQ 092
ARQ 761
ARQ 751
Oncology Clinical Trials
Rare Diseases Clinical Trials
Science
Targeted Approach
BTK Inhibitor (ARQ 531)
Early Stage Programs
Publications & Presentations
Investors & Media
Press Releases
Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor & Media FAQs
Investor & Media Contact
Contact
Twitter
LinkedIn
×
Close
What are you looking for?
×
Close
Contact Us
*Required fields
×
Close
Contact Us
*Required fields
